Related Experiment Video

Updated: Sep 21, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Gene therapy for colorectal cancer

D J Kerr1, L W Seymour, F Maruta

  • 1Department of Clinical Pharmacology, Radcliffe Infirmary, University of Oxford, Woodstock Road, Oxford, OX2 6HE, UK.

Expert Opinion on Biological Therapy
|July 26, 2003
PubMed

Insights

Gene therapy shows promise for advanced colorectal cancer, but faces challenges. Improved targeting and gene transfer are key for clinical success in treating this public health problem.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biotechnology

Background:

  • Colorectal cancer (CRC) presents a significant global health challenge.
  • Conventional treatments are often ineffective for advanced or recurrent CRC.
  • Gene therapy offers a potential alternative for difficult-to-treat CRC cases.

Purpose of the Study:

  • To review the current state and potential of gene therapy for colorectal cancer.
  • To identify key strategies and challenges in CRC gene therapy.
  • To discuss future directions for gene therapy in CRC treatment.

Main Methods:

  • Exploration of various gene therapy strategies, including mutant gene correction, prodrug activation, immune stimulation, and oncolytic viruses.
  • Review of preclinical and early clinical development findings.
  • Analysis of obstacles hindering clinical application.

Main Results:

  • Preclinical studies demonstrate promising results for gene therapy in CRC models.
  • Current clinical development is in its early stages with limited therapeutic benefit observed.
  • Key challenges include poor vector targeting selectivity and inefficient gene transfer.

Conclusions:

  • Gene therapy holds significant potential for advanced or recurrent colorectal cancer.
  • Overcoming vector targeting and gene transfer inefficiencies is crucial.
  • Advancements in tumor-selective vectors could accelerate clinical adoption for CRC treatment.

More Related Videos

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres06:52

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

A Genetically Engineered Mouse Model of Sporadic Colorectal Cancer06:01

A Genetically Engineered Mouse Model of Sporadic Colorectal Cancer

Published on: July 6, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Gene Therapy01:22

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...